Navigation Links
Tengion Reports Fourth Quarter and Full Year 2011 Financial Results
Date:3/26/2012

an be accessed from the Investors section of the Company's website or directly at http://edge.media-server.com/m/p/o4v89uyi/lan/en. The webcast will also be archived on the website.

About TengionTengion, a clinical-stage regenerative medicine company, is focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  Using its Organ Regeneration Platform™, the Company creates neo-organs using a patient's own cells, or autologous cells.  Tengion's proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues.  The Company's product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Forward-Looking StatementsCertain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... J. Fox Foundation for Parkinson,s Research awarded about $2.9 ... drugs already approved in other disease indications for potential ... are already known to be safe for humans, they ... use in Parkinson,s patients if they prove effective in ...
... 12 Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ... development of drugs for the treatment of human viral ... initiated a proof-of-concept study of IDX184, a liver-targeted nucleotide ... Investigational New Drug application (IND) with the U.S. Food ...
Cached Medicine Technology:Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... Four years since the release of their debut ... the marriage of Avasa & Matthew Love – the duo are ... for release through White Swan Records on February 24, 2015. , ... sacred path available to all of us to walk out of ...
(Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Canada are raising a hue and cry over inadequate facilities in ... ill-equipped and many a times patients have to be treated in ... the B.C. Nurses' Union president Deb McPherson said that the status ... have no privacy and no direct access to a washroom, or ...
... reporting that the traditional method of assessing the heart ... danger //of missing one-third of women who are predisposed ... ,Roger Blumenthal, M.D., an associate professor and director ... Hopkins University School of Medicine and its Heart Institute ...
... The health services in Australia’s Townsville will be revolutionized after ... the James Cook University (JCU).// A rural medical school has ... JCU. The University’s new clinic will cost A$ 3 million, ... This will serve to give them experience with regard medicine ...
... to Food science and consumer acceptance in Norway the ... do experts to cheese.// ,The food compared was ... expert dairy assessors. The rating was based on reaction ... was difference of opinion in both factions. As a ...
... Researchers from the Pennsylvania State University are trying to determine ... the zebra fish. The team led by Mark Shriver studied ... change in their key gene plays a major role in ... of Science, may not only help explain why people of ...
... against cancer focusing at the molecular and genetic levels, ... coming under increasing scrutiny.// Now scientists at the University ... these supporting cells are indeed key players in the ... ,These findings were arrived at after studying a ...
Cached Medicine News:Health News:Calcium Levels Could Indicate Future Heart Disease Risk 2Health News:Cancer Cells Trigger Supporting Cells to Turn Cancerous 2
For the quantitative in vitro determination of Microalbumin in urine....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with kaolin activator....
Medicine Products: